Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-168 in Fuchs Endothelial Corneal Dystrophy
NCT07024693Phase 2Recruiting
- Sponsor
- Design Therapeutics
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DT-168 in Fuchs endothelial corneal dystrophy (FECD), sponsored by Design Therapeutics. Started Jul 2025; status: recruiting.
02
Drugs
DT-168
03
Conditions
Fuchs endothelial corneal dystrophy (FECD)
Beyond the preview
Go deeper on NCT07024693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024693.